Our screening assay with 1535 well-characterised compounds also revealed that differentially expressed ERβ could be a potential target for E-cadherin-deficient DGC, and provided convincing evidence of clinical use of oestrogen drugs including mestranol for prevention and treatment of this subtype of GC. This evidence concerns the gene ESR2 and gastric cancer.